Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer

The Lancet Oncology

Volumn 12, Issue 12, 2011, Pages 1109-1117

  Coleman, Robert L ^a   Duska, Linda R ^b   Ramirez, Pedro T ^a   Heymach, John V ^a   Kamat, Aparna A ^a   Modesitt, Susan C ^b   Schmeler, Kathleen M ^a   Iyer, Revathy B ^a   Garcia, Michael E ^a   Miller, Debbie L ^a   Jackson, Edward F ^c   Ng, Chaan S ^a   Kundra, Vikas ^a   Jaffe, Robert ^c   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BIOLOGICAL MARKER; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; PLATINUM COMPLEX;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL THERAPY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; DIGESTIVE SYSTEM FISTULA; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DYSPNEA; EPIPHORA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; IMAGING; INFECTION; LEUKOCYTE; LEUKOPENIA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NAIL; NAIL INFECTION; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEINURIA; RECURRENT CANCER; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSIENT ISCHEMIC ATTACK; ULCER; UTERINE TUBE CARCINOMA; VOICE CHANGE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RECOMBINANT FUSION PROTEINS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 81255185158     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70244-3     Document Type: Article

References (47)

1. Holash J, Davis S, Papadopoulos N, et al. VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002, 99:11393-11398.
2. Kim ES, Serur A, Huang J, et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 2002, 99:11399-11404.
3. Tew WP, Gordon M, Murren J, et al. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res 2010, 16:358-366.
4. Moroney JW, Sood AK, Coleman RL Aflibercept in epithelial ovarian carcinoma. Future Oncol 2009, 5:591-600.
5. Tew WP, Colombo N, Ray-Coquard I, et al. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study. Proc Am Soc Clin Oncol 2007, 25. abstr 5508.
6. Vergote I, Amant F, Advani S, et al. Intravenous aflibercept (VEGF Trap) in advanced ovarian cancer patients with recurrent symptomatic malignant ascites: main efficacy and safety results of a phase II, randomized, double-blind, placebo-controlled study. Proc Eur Soc Gynecol Oncol 2009, 16. abstr 4.
7. Grant DS, Williams TL, Zahaczewsky M, et al. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 2003, 104:121-129.
8. Cohn DE, Valmadre S, Resnick KE, et al. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 2006, 102:134-139.
9. Hurt JD, Richardson DL, Seamon LG, et al. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol 2009, 115:396-400.
10. O'Malley DM, Richardson DL, Rheaume PS, et al. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol 2011, 121:269-272.
11. Hu L, Hofmann J, Holash J, et al. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005, 11:6966-6971.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
13. Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010, 28:207-214.
14. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999, 5:434-438.
15. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999, 85:221-228.
16. Kalka C, Masuda H, Takahashi T, et al. Vascular endothelial growth factor (165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000, 86:1198-1202.
17. Kalka C, Tehrani H, Laudenberg B, et al. VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. Ann Thorac Surg 2000, 70:829-834.
18. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000, 95:952-958.
19. Capillo M, Mancuso P, Gobbi A, et al. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 2003, 9:377-382.
20. Desai NP, Trieu V, Hwang LY, et al. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008, 19:899-909.
21. Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003, 9:5721-5728.
22. Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003, 100:7785-7790.
23. Tillmanns TD, Lowe MP, Schwartzbert LS, et al. A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Proc Am Soc Clin Oncol 2010, 28. abstr 5009.
24. Labidi SI, Bachelot T, Ray-Coquard I, et al. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clin Breast Cancer 2009, 9:118-121.
25. Reynolds C, Barrera D, Jotte R, et al. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2009, 4:1537-1543.
26. Hurt JD, Richardson DL, Seamon LG, et al. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol 2009, 115:396-400.
27. Gonzalez-Cao M, Viteri S, Diaz-Lagares A, et al. Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma. Oncology 2008, 74:12-16.
28. Link JS, Waisman JR, Nguyen B, et al. Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer. Clin Breast Cancer 2007, 7:779-783.
29. Cohn DE, Valmadre S, Resnick KE, et al. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 2006, 102:134-139.
30. Gerber HP, Ferrara N Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005, 65:671-680.
31. Woodward EJ, Twelves C Scheduling of taxanes: a review. Curr Clin Pharmacol 2010, 5:226-231.
32. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001, 61:3369-3372.
33. Hotchkiss KA, Ashton AW, Mahmood R, et al. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther 2002, 1:1191-1200.
34. Albertsson P, Lennernas B, Norrby K On metronomic chemotherapy: modulation of angiogenesis mediated by VEGE-A. Acta Oncol 2006, 45:144-155.
35. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996, 2:1843-1849.
36. Chen CA, Ho CM, Chang MC, et al. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol Ther 2010, 18:1233-1243.
37. Damber JE, Vallbo C, Albertsson P, et al. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol 2006, 58:354-360.
38. Drevs J, Fakler J, Eisele S, et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004, 24:1759-1763.
39. Hata K, Osaki M, Dhar DK, et al. Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line. Cancer Chemother Pharmacol 2004, 53:68-74.
40. Hu L, Hofmann J, Holash J, et al. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005, 11:6966-6971.
41. Klauber N, Parangi S, Flynn E, et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997, 57:81-86.
42. Lau DH, Xue L, Young LJ, et al. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 1999, 14:31-36.
43. Pasquier E, Honore S, Pourroy B, et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005, 65:2433-2440.
44. Wang J, Lou P, Lesniewski R, et al. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003, 14:13-19.
45. Lau D, Guo L, Gandara D, et al. Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?. Anticancer Drugs 2004, 15:871-875.
46. Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003, 88:130-135.
47. Katsumata N, Tsunematsu R, Tanaka K, et al. A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study. Ann Oncol 2000, 11:1531-1536.